White Paper:
The High Bar for Gene Therapy CMC
How drug developers can step up to meet regulatory expectations for gene therapy chemistry manufacturing and controls
After well publicized stumbling blocks in the late-90s, vigor was restored to the gene therapy field in 2017 when the U.S. FDA greenlighted two chimeric antigen receptor (CAR) T-cell treatments for acute lymphoblastic leukemia, followed by the first directly administered gene therapy, developed to treat a hereditary form of vision loss.
Years later, there are still only a handful of approvals in the space (two gene therapies and five CAR-T cell therapies),
but pipelines are brimming with potential.
Download the Whitepaper
Complete the form below to download your copy!
You might also be interested in…
Navigating the European Union’s (EU) Drug Device Combination Product Regulatory Changes
White Paper: Navigating the European Union’s (EU) Drug Device Combination Product Regulatory ChangesThe European therapeutics market has been working to manage the upheaval caused by Brexit and is now working its way through yet another challenge: the medical devices...
Process Validation for Expedited Approval Drugs
White Paper: Process Validation and Regulatory Review in the Age of Expedited Approval Drugs Expedited approval drugs have profoundly changed the thinking and approach to Process Validation and other CMC activities. When working on the development of an expedited...
Cell Therapies – Overcoming Challenges Within the Regulatory Framework
White Paper: Cell Therapies Come of Age: Overcoming Challenges Within the Regulatory FrameworkWithin the cell therapy arena, regulators, the medical community and industry alike are often confronted with an unsettling question. What is this, really? Should a given...